Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007196
Chunk: 14

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 14
---
 filings, including Investigational New Drug applications, with respect to any of our product candidates 
 and the receipt of any regulatory approvals;                                                                                                |

| · | the anticipated medical benefits of our product candidates; |

| · | the difficulties in obtaining and maintaining regulatory approval of our product candidates, and the labeling 
 under any approval we may obtain;                                                                             |

| · | the success and timing of the potential commercial development of our product candidates and any product 
 candidates we may acquire in the future, including eRapa, tolimidone and MTX110;                         |

| · | our plans and ability to develop and commercialize our product candidates and any product candidates we 
 may acquire in the future;                                                                              |

| · | the ability to manufacture products in third-party facilities; |

| · | the rate and degree of market acceptance of any of our product candidates; |

| 10 |

| · | the successful development of our commercialization capabilities, including our internal sales and marketing 
 capabilities;                                                                                                |

| · | obtaining and maintaining intellectual property protection for our product candidates and our proprietary 
 technology;                                                                                               |

| · | the success of competing therapies and products that are or become available; |

| · | the success of any future acquisitions or other strategic transactions; |

| · | the difficulties of integrating the business of any future acquisitions into our own; |

| · | cybersecurity and other cyber incidents; |

| · | industry trends; |

| · | the impact of government laws and regulations; |

| · | regulatory, economic and political developments in the United Kingdom, the European Union, the United        
 States and other foreign countries, including any impact from the United Kingdom leaving the European Union; |

| · | the difficulties doing business internationally; |

| · | the ownership of our Ordinary Shares and Depositary Shares; |

| · | our ability to continue to meet the listing criteria required to remain listed on the NASDAQ Capital Market; |

| · | our ability to recruit or retain key scientific or management personnel or to retain our senior management; |

| · | the impact and costs and expenses of any litigation we may be subject to now or in the future; |

| · | the performance of third parties, including joint venture partners, our current sales force, our collaborators, 
 third-party suppliers and parties to our licensing agreements; and                                              |

| · | other risks and uncertainties, including those described in “Risk Factors” in this 
 prospectus.                                                                        |

Any forward-looking statements
that we make in this prospectus speak only